Global Branded Generics Market Size & Outlook, 2021-2030

The branded generics industry worldwide is expected to reach a projected revenue of US$ 375,952.4 million by 2030. A compound annual growth rate of 5.7% is expected of the worldwide branded generics industry from 2022 to 2030.
Revenue, 2021 (US$M)
$229,064.0
Forecast, 2030 (US$M)
$375,952.4
CAGR, 2022 - 2030
5.7%
Report Coverage
Worldwide

Global branded generics market highlights

  • The global branded generics market generated a revenue of USD 229.1 billion in 2021 and is expected to reach USD 376.0 billion by 2030.
  • The market is expected to grow at a CAGR (2022 - 2030) of 5.7% by 2030.
  • In terms of segment, anti-hypertensive accounted for a revenue of USD 35.9 billion in 2021.
  • Hormones is the most lucrative drug class segment registering the fastest growth during the forecast period.
  • In terms of region, Asia Pacific was the largest revenue generating market in 2021.
  • Country-wise, France is expected to register the highest CAGR from 2022 to 2030.

Global data book summary

Market revenue in 2021USD 229.1 billion
Market revenue in 2030USD 376.0 billion
Growth rate5.7% (CAGR from 2021 to 2030)
Largest segmentAnti-hypertensive
Fastest growing segmentHormones
Historical data covered2018 - 2020
Base year for estimation2021
Forecast period covered2022 - 2030
Quantitative unitsRevenue in USD billion
Market segmentationAlkylating Agents, Antimetabolites, Hormones, Anti-hypertensive, Lipid Lowering drugs, Anti-depressants, Anti-psychotics, Anti-epileptics

Other key industry trends

  • In terms of revenue, the North America accounted for 19.8% of the global branded generics market in 2021.
  • By country, the U.S. is projected to lead the global market in terms of revenue in 2030.
  • By country, France is the fastest growing regional market and is projected to reach USD 6.8 billion by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Branded Generics Market Companies

Name Profile # Employees HQ Website

Global branded generics market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to branded generics market will help companies and investors design strategic landscapes.


Anti-hypertensive was the largest segment with a revenue share of 15.67% in 2021. Horizon Databook has segmented the Global branded generics market based on alkylating agents, antimetabolites, hormones, anti-hypertensive, lipid lowering drugs, anti-depressants, anti-psychotics, anti-epileptics covering the revenue growth of each sub-segment from 2018 to 2030.


  • Global Branded Generics Drug Class Outlook (Revenue, USD Million, 2018-2030)
    • Alkylating Agents
    • Antimetabolites
    • Hormones
    • Anti-hypertensive
    • Lipid Lowering drugs
    • Anti-depressants
    • Anti-psychotics
    • Anti-epileptics
    • Others
  • Global Branded Generics Application Outlook (Revenue, USD Million, 2018-2030)
    • Oncology
    • Cardiovascular Diseases
    • Neurological Diseases
    • Gastrointestinal Diseases
    • Dermatological diseases
    • Acute and Chronic Pain
    • Others
  • Global Branded Generics Route of Administration Outlook (Revenue, USD Million, 2018-2030)
    • Topical
    • Oral
    • Parenteral
    • Others
  • Global Branded Generics Distribution Channel Outlook (Revenue, USD Million, 2018-2030)
    • Hospital Pharmacy
    • Retail Pharmacy
    • Online Pharmacy & Others

Reasons to subscribe to Global branded generics market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Global branded generics market databook

  • Our clientele includes a mix of branded generics market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of global-level data and insights on the Global branded generics market , including forecasts for subscribers. This global databook contains high-level insights into Global branded generics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

Global branded generics market size, by regions, 2018-2030 (US$M)

Top 10 countries: Branded generics market size, 2021 (US$M)

Global branded generics market share, by drug class, 2021 & 2030 (%, US$M)

Branded generics market: Opportunity assessment by country

Global branded generics market, by region, 2021 (US$M)

Global branded generics market size, by regions, 2018-2030 (US$M)

Drug Class 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR
North America 39,033.4 40,530.9 43,678.6 45,421.6 47,334.4 49,395.5 51,617.0 54,012.0 56,595.3 59,382.8 62,349.6 65,508.9 68,874.5 4.7%
Europe 30,707.5 31,940.4 34,481.2 35,920.8 37,500.9 39,205.3 41,044.6 43,030.1 45,174.5 47,491.6 49,963.0 52,600.1 55,415.4 4.9%
Asia Pacific 88,228.2 93,053.7 101,859.1 107,593.1 113,893.4 120,730.7 128,156.9 136,229.4 145,011.7 154,574.7 164,885.1 176,007.8 188,013.8 6.4%
Latin America 17,419.7 18,145.7 19,618.1 20,467.8 21,400.5 22,407.5 23,495.1 24,670.4 25,941.0 27,315.6 28,783.9 30,353.1 32,031.1 5.1%
MEA 16,588.3 17,329.3 18,789.7 19,660.7 20,617.1 21,651.2 22,769.9 23,980.8 25,292.3 26,713.7 28,236.3 29,867.9 31,617.6 5.4%
Overall 191,977.0 200,999.9 218,426.6 229,064.0 240,746.3 253,390.2 267,083.5 281,922.7 298,014.8 315,478.4 334,217.9 354,337.8 375,952.4 5.7%

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more